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INTRODUCTION
It has been reported that the incidence of thyroid nodule
in Graves’ disease patients varies from 10% to 35% (1-9). It
is possible that high-resolution ultrasonography during ini-
tial diagnosis allowed identification of small thyroid nodules
in Graves’ disease patients. However, the prevalence of dif-
ferentiated thyroid cancer (DTC) in Graves’ disease patients
remains as a matter of debate, with previous reports show-
ing the prevalence was 0.3-16.6% (1-14). 
The biologic behaviors and optimal management of DTC
with concurrent Graves’ disease are still controversial. Some
investigators have reported that patients of DTC associated
with Graves’ disease experienced a more aggressive course than
euthyroid patients (15, 16). Pellegriti et al. (17) suggested
that the extent of surgery in such patients must be extensive,
involving at least a total thyroidectomy and lymph node dis-
section followed by 131radioactive iodine therapy (RI). In con-
trast, others reported that the aggressiveness and the treat-
ment outcomes of DTC in Graves’ disease patients are simi-
lar to those of euthyroid patients (6, 18). Thus, there remains
controversy as to the optimal extent of surgery in these cases. 
The aims of the present study were to identify clinicopatho-
logic features, treatment outcome, and indicators for pre-
dicting locoregional recurrences and to suggest the optimal
extent of surgery in DTC patients with concurrent Graves’
disease. 
MATERIALS AND METHODS
Study patients
During the 20-yr period from 1986 to 2005, 779 patients
with Graves’ disease underwent surgery at our hospital. The
diagnosis of Graves’ disease was based on the history and
signs of thyrotoxicosis, increased levels of serum triiodothy-
ronine (T3) and thyroxine (T4), low levels of thyroid-stimu-
lating hormone (TSH), the presence of autoantibodies (thy-
roid stimulating antibodies [TSAbs] and/or antiperoxidase
antibodies), increased radionuclide uptake at scintiscan, and
the histological features of diffuse hyperplasia of the thyroid
gland. Patients were treated preoperatively with propylth-
iouracil, cabimazole, or methimazole. They also received Lugol
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Clinicopathologic Features and Treatment Outcomes in Differentiated
Thyroid Carcinoma Patients with Concurrent Graves' Disease
The clinical behaviors and treatment outcomes of thyroid carcinomas in patients
with Graves’ disease is a matter of controversy. This study aimed to identify the
clinicopathologic features, treatment outcome, and the indicators for predicting recur-
rence, and to suggest the optimal extent of surgery in these patients. We retrospec-
tively analyzed data of 58 patients who underwent surgical treatment for  differenti-
ated thyroid cancer and concurrent Graves’ disease. The follow-up period ranged
from 23 to 260 months (mean±standard devuation, 116.8±54.0). In our series,
the mean age was 40.8±12.7 yr (range, 15-70), with a male-to-female ratio of 1:
6.25. The mean tumor size was 13±9 mm (range, 3-62). The surgical methods
included 19 cases of total thyroidectomy, 38 cases of subtotal thyroidectomy, and
1 case of completion total thyroidectomy. Locoregional recurrence occurred in four
patients (6.9%). The 10-yr overall survival and disease-free survival of patients were
95.8% and 91.1%, respectively. Age over 45 yr (p=0.031), tumor size over 10 mm
(p=0.049), multiplicity (p=0.007), extracapsular invasion (p=0.021), and clinical can-
cer (p=0.035) were significantly more prevalent in patients with locoregional recur-
rence than in those without recurrence. We recommend that Graves’ disease patients
should undergo regular ultrasonography screening for early detection of thyroid
carcinoma. We also suggest that the choice of extent of surgery should depend on
the diagnostic timing (clinical or incidental) and factors for predicting recurrence. 
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solution (8 drops per 6 hr) for 7 to 10 days before surgery.
The indications for surgery were the presence of a large com-
pressive goiter, recurrent thyrotoxicosis, side effects of anti-
thyroid medications, unlikelihood or inability of taking medi-
cine, presence of cold nodules on thyroid scanning, and sus-
picion of malignancy on fine needle aspiration biopsy. 
Diagnostic timing
Study patients were classified as clinically overt carcino-
ma or incidental carcinoma. In clinically overt carcinoma, a
patient with Graves’ disease was found to have a specific
symptom or sign and thyroid carcinoma was diagnosed pre-
operatively. However, in incidental carcinoma, Graves’ dis-
ease was the only clinical diagnosis before operation and thy-
roid carcinoma was identified during surgery or following
histological examination of permanent sections.
Surgical method
Patients with incidental carcinoma underwent a bilateral
subtotal thyroidectomy or a Hartley-Dunhill operation (16)
(a unilateral lobectomy with a contralateral subtotal lobec-
tomy, leaving 4-6 g of thyroid tissue). Intraoperative frozen
sections were carried out in all the suspicious lesions. In case
of clinical carcinoma, we performed the operative methods
according to the TNM classification system (T, tumor size;
N, involvement of lymph nodes; M, presence of distant metas-
tasis) (19). 
Postoperative follow-up
All patients were postoperatively followed up every 3-6
months. Patients were evaluated for locoregional or distant
metastasis by the following diagnostic methods: serum thy-
roglobulin/anti-thyroglobulin antibody level, ultrasonogra-
phy, computed tomography, radioiodine scintigraphy.
Statistical analysis
Comparisons between groups were performed using Mann-
Whitney U test and Fisher’s exact test. Estimated survival
rates were calculated by the Kaplan-Meier method. Statisti-
cal significance was set at p<0.05.
RESULTS
Clinical characteristics 
Fifty-eight cases of DTC (7.4%) were diagnosed among
779 Graves’ disease patients who underwent thyroidectomy
between 1986 and 2005. The study enrolled 8 male and 50
female patients with a mean age of 40.8±12.7 yr (range,
15-70). No patients had previous history of radiation expo-
sure or radioactive iodine therapy. Twenty-six cases of clini-
cally overt thyroid carcinomas were diagnosed among 779
Graves’ disease patients (3.3%). The prevalence of inciden-
tal carcinoma in the Graves’ disease patients was calculated
as 4.2% (32 patients with occult thyroid carcinoma out of
753 patients who underwent operation represented only part
of Graves’ disease). Comparison of clinical findings of inci-
dental and clinical carcinoma patients revealed no difference
between the two groups in terms of duration of thyrotoxic
symptoms, T3/T4 serum levels before the administration of
antithyroid medication, and postoperative 6-week serum
concentration of thyroglobulin/TSH (Table 1).
Surgical treatment and histopathologic findings
Of the 26 patients with clinical carcinoma, 14 underwent
total thyroidectomy and 12 underwent subtotal thyroidec-
tomy. Of the 32 patients with incidental carcinoma, 5 under-
went total thyroidectomy and 26 subtotal thyroidectomy
(Table 2). There was one patient of completion thyroidecto-
Characteristics Total (n=58) Clinical cancer (n=26) Incidental cancer (n=32) p value
Gender
Male 8 4 4
Female 50 22 28 0.751*
Mean age (yr) 40.84±12.69 42.50±14.87 39.50±10.67 0.376
�
Tumor size (mm) 13.14±9.78 19.52±14.43 7.32±6.76 0.017
�
Duration of thyrotoxic 27.62±26.40 29.54±27.90 26.06±25.46 0.622
�
symptoms (month)
Serum T4 (mM/L)
� 212.43±13.64 226.32±31.46 204.19±19.76 0.196
�
Serum T3 (mM/L)
� 7.98±0.76 8.02±0.99 7.42±0.85 0.241
�
Thyroglobulin (μ g/L)
� 13.41±17.35 11.540±12.64 15.13±10.04 0.482
�
Serum TSH (mIU/L)
� 19.32±21.08 22.06±20.19 17.78±24.64 0.186
�
Table 1. Clinical characteristics of clinical and incidental cancers
Mean±SD: median, with the range presented in parenthesis.
*, Fisher’s exact test; 
� , Mann-Whitney test; 
� , before antithyroid medication; 
�, six-week postoperative serum level.
T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone.798 J. Lee, K.H. Nam, W.Y. Chung, et al.
my, who had initially underwent a subtotal thyroidectomy
for Graves’ disease; the subsequent histopathology analysis,
however, showed a widely invasive follicular carcinoma. Of
the total 58 carcinomas, 57 (98.3%) were papillary thyroid
carcinoma and 1 (1.7%) was a follicular thyroid carcinoma.
The mean tumor size was 13±9 mm in diameter (range,
3-62). Extracapsular invasion and invasion to adjacent struc-
ture were found in 23 (39.7%) and 3 cases (5.2%), respec-
tively. Multiple lesions were noted in 18 cases (31.0%). Cen-
tral compartment node metastasis and lateral cervical lymph
node metastasis were shown in 18 (31.0%) and 5 (8.6%)
cases, respectively. 
Postoperative adjuvant therapy
Sixteen patients treated with total thyroidectomy under-
went postoperative adjuvant RI. Eleven of these patients
TT, total thyroidectomy; MRND, modified radical neck dissection; CCND,
central compartment neck dissection.
Characteristics
Total 
(n=58) (%)
Clinical 
cancer 
(n=26) (%)
Incidental 
cancer
(n=32) (%)
Bilateral subtotal  22 (37.9) 22 (68.8)
thyroidectomy
Dunhill procedure 4 (6.9) 4 (12.5)
TT with CCND 14 (24.2)  9 (34.6) 5 (15.6)
Ipsilateral total and  12 (20.7) 12 (46.2)
contralateral subtotal 
thyroidectomy with CCND
Total thyroidectomy with 5 (8.6) 5 (19.2)
MRND
Completion thyroidectomy 1 (1.7) 1 (3.1)
Table 2. Surgical methods
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Fig. 1. The overall (A) and disease-free (B) survival of patients who underwent surgical treatment for differentiated thyroid carcinoma and
concurrent Graves’ disease. 
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B
Case 1 Case 2 Case 3 Case 4
Gender F F F F
Age (yr) 48 21 61 46
Duration of recurrence (months) 153 91 167 107
Tumor size (mm) 17 9 24 16
Clinical/incidental Clinical Clinical Clinical Clinical 
TNM T3N1aM0 T3N1aM0 T3N0M0 T3N1bM0
Stage Stage III Stage I Stage III Stage IVa
1st operation TT /c CCND TT /c CCND TT /c CCND TT /c MRND
Site of LR Strap muscle Thyroid bed Thyroid bed Thyroid bed
LCLN LCLN
Treatment of LR Reoperation+H-RI No treatment Reoperation+H-RI  No treatment
Treatment outcome Remission Death Remission Death
Cause of death Ovary cancer /c SM LR
Table 3. Disease patterns in four locoregional recurrence patients
Clinical/incidental, clinical cancer or incidental cancer; TT, total thyroidectomy; /c,with; CCND, central compartment node dissection; MRND, modified
radical neck dissection; LR, local recurrence; LCLN, lateral cervical lymph node; H-RI, high-dose radioactive iodine threapy; SM, systemic metastasis.Differentiated Thyroid Cancer in Patients with Graves’ Disease 799
received low-dose (30-60 mCi) therapy for ablation of resid-
ual thyroid tissue. Four patients in which lateral cervical
lymph node metastasis was present received high-dose (150-
250 mCi) therapy. 
Treatment outcome and Indicators for predicting recur-
rence
The mean follow-up period was 116.8±54.0 months
(range, 23-260). For all the patients, the 10-yr overall sur-
vival and disease-free survival rates were calculated to be
95.8% and 91.1%, respectively (Fig. 1). Local recurrence
was identified in 4 patients (6.9%), all of whom belonged
to the clinical carcinoma group. The mean duration of recur-
rence was 129±36 months (range, 91-167), with no patients
diagnosed with distant metastases during the follow-up. 
Of the 4 loco-regional recurrence patients, 2 patients under-
went re-operation and high-dose RI. Neither of these patients
has shown any evidence of recurrence up to now (77 months
and 54 months, respectively) since the second operation. For
the other 2 patients, local recurrence was noted in the thy-
roid bed and lateral cervical lymph nodes, respectively (Table
3). These patients were not treated for this local recurrence
since both refused to undergo treatment: one died of aggres-
siveness of local recurrence 132 months after the initial thy-
roidectomy and the other of combined ovary cancer with
systemic metastasis 98 months after the surgery.
The patient age of over 45 yr, tumor size, multiplicity,
extracapsular invasion, and clinical cancer were significant
factors in predicting the locoregional recurrence (Table 4). 
DISCUSSION
The prevalence of thyroid carcinoma in Graves’ disease has
been reported to be from 0.3% to 16.6% (1-14). It is sug-
gested that part of the explanation for the wide variation in
incidence could be due to differences in the extent of resec-
tion as well as in the number of histologic sections examined
per specimen (20). Moreover, the increasing use of high res-
olution ultrasonography has revealed greater numbers of thy-
roid nodules, and the routine use of such devices has allowed
diagnosis of small thyroid carcinoma in Graves’ disease pati-
ents. The 7.4% prevalence found in our work seems to be
relevant to that found in other reports. 
Controversy remains regarding the pathogenic relation-
ship between thyroid carcinoma and Graves’ disease. It is
well known that the binding of TSH to TSH receptors might
promote the growth of cancer cells in euthyroid patients with
thyroid carcinoma. In Graves’ disease in which serum TSH
is suppressed, TSAbs rather than TSH are reported to acti-
vate the TSH receptor (16, 21, 22). Some studies showed that
autoimmune responses in Graves’ disease including TSAbs
are closely linked to angiogenesis, which plays a crucial role
Parameters
Recurrence
(n=4) (%)
No recurrence
(n=54) (%)
p
value
Gender
Male 8 (13.8)
Female 4 (6.98) 46 (79.3) 0.411*
Age (yr)
≥45 3 (5.2) 15 (25.9)
<45 1 (1.7) 39 (67.2) 0.031*
Duration of thyrotoxic 31.25±19.87 25.45±22.16 0.513
�
symptoms
Serum T4 (mM/L)
� 198.33±12.13 209.11±21.01 0.634
�
Serum T3 (mM/L)
� 7.2±0.9 6.9±0.7 0.207
�
Thyroglobulin (μ g/L)
� 20.9±22.3 3.4±27.8 0.273
�
Serum TSH (mIU/L)
� 16.3±21.1 12.1±16.1 0.384
�
Clinical/incidental cancer
Clinical cancer 4 (6.9) 22 (37.9)
Incidental cancer 32 (55.2) 0.035*
Pathology
Papillary  4 (6.8) 53 (91.4)
Follicular 1 (1.7) 0.931*
Tumor size (mm)
>10 3 (5.2) 12 (20.7)
≤10 1 (1.7) 42 (72.4) 0.049*
Extracapsular invasion
Yes 4 (6.9) 19 (32.8)
No 35 (60.3) 0.021*
Invasion to adjacent structure
Yes 1 (1.7) 2 (3.4)
No 3 (5.2) 52 (89.7) 0.196*
Multiplicity
Yes 4 (6.9) 14 (24.1)
No 40 (70.0) 0.007*
Central lymph node metastasis
Yes 3 (5.2) 15 (25.9)
No 1 (1.7) 39 (67.2) 0.084*
Lateral cervical lymph node metastasis
Yes 1 (1.7) 4 (6.9)
No 3 (5.2) 50 (86.2) 0.310*
Extent of thyroidectomy
TT 1 (1.7) 19 (32.8)
Less than TT 3 (5.2) 35 (92.1) 0.572*
Central compartment lymph node dissection
Yes 3 (5.2) 15 (25.9)
No 1 (1.7) 39 (67.2) 0.084*
Postoperative 131 RI
Yes 2 (3.4) 14 (24.1)
No 2 (3.4) 40 (69.0) 0.303*
Table 4. Parameters predicting recurrence of differentiated thy-
roid cancer associated with Graves’ disease
Mean±SD: median with the range presented in parenthesis.
*, Fishers exact test; 
� , Mann-Whitney U test; 
� , measured before antithy-
roid treatment; 
�, measured after postoperative six week.
T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone;
TT, total thyroidectomy; RI, radioactive iodine therapy.800 J. Lee, K.H. Nam, W.Y. Chung, et al.
in tumor growth and development (15, 21, 23). Therefore,
patients of Graves’ disease with DTC has been found to have
a worse clinical outcome than euthyroid patients with DTC
(4, 17, 18, 24, 25). In contrast, other investigators suggest-
ed that Graves’ disease was not related to the aggressiveness
of coexisting thyroid carcinoma (6, 9, 26). These studies iden-
tified that the severity of thyrotoxicosis was not related to
the prognosis of DTC patients with concurrent Graves’ dis-
ease (27-29). In the present series of our work, the 10-yr over-
all and disease-free survival rates were 95.8% and 91.1%,
respectively, showing favorable treatment outcomes in these
patients, and the severity of thyrotoxicosis and serum thy-
roid hormone levels did not affect the prognosis.
A few studies examined recurrence-predicting indicators
in patients of DTC with concurrent Graves’ disease. Although
some authors suggested patient age, tumor size and preop-
erative T3 levels are significant factors to predict metastasis
(6, 30), recent studies indicate that the most crucial prog-
nostic indicator is diagnostic timing (clinical or incidental)
(26, 31). In the present investigation, patient age over 45
yr, the presence of extracapsular invasion, multiplicity, and
clinical cancer, but not severity of thyrotoxicosis, were cor-
related with a high recurrence rate.
Debate continues regarding the proper extent of surgery
for Graves’ disease patients with DTC. There has been a pref-
erence for radical surgery in patients with DTC with concur-
rent Graves’ disease, involving at least total thyroidectomy
and lymph node dissection followed by RI (16, 17). How-
ever, recent approaches have suggested that the choice of
surgical strategies depend on the diagnostic timing and stage
of tumor (26-31). This indicates that the extent of surgery
should be similar for thyroid cancer in euthyroid patients,
and that subtotal thyroidectomy is sufficient, whereas addi-
tional completion total thyroidectomy is not necessary in
incidental cases. In the present investigation, neither the
extent of thyroidectomy nor the presence of lymph node dis-
section was found to be correlated with the recurrence rate.
Therefore, complete thyroidectomy might be helpful only in
cases in which indicators predicting recurrence are present.
In this study, two of the four patients who had local recur-
rence underwent second operation and survived with no fur-
ther episodes. The other two patients refused further treat-
ment and died. Even though the present study involved only
a small number of patients, the findings suggest that early
detection and active treatment lead to a good prognosis even
in cases of local recurrence.
Nevertheless, we encountered with several limitations when
we tried to investigate the treatment outcome and signifi-
cant factors to predict recurrence in thyroid carcinoma pati-
ents with concurrent Graves’ disease. First, there were only a
limited number of patients. Second, the natural course of
DTC is characterized by very slow progression, therefore, our
observation period might not have been enough to detect the
evolution from silent disease to overt clinical metastasis. 
In conclusion, we recommend that patients of Graves’ dis-
ease should undergo regular screening both meticulous phys-
ical examination and ultrasonography for early detection of
thyroid carcinoma. Our present results show that predicting
factors for recurrence in DTC patients with concurrent Graves’
disease were age over 45 yr, tumor size over 10 mm, multi-
plicity, extracapsular invasion, and clinical carcinoma. We
also suggest that the choice of extent of surgery in these pati-
ents should depend on the diagnostic timing (clinical or inci-
dental) and factors for predicting recurrences, and that a subto-
tal thyroidectomy would be sufficient in incidental carcino-
mas without factors predicting recurrence. On the other hand,
in clinical cancers or in cases where recurrence-predicting
factors are present, at least a total thyroidectomy with lymph
node dissection might be helpful. 
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